Menu

Pulmonary Hypertension (PH)

Pulmonary Hypertension (PH) is a disease of the pulmonary vasculature, leading to shortness of breath, dizziness, fainting, and ultimately right heart failure. A total of approximately 100 million people worldwide suffer from one of the forms of Pulmonary Hypertension. Vascular pathology is characterized by vasoconstriction of the pulmonary vessels and abnormal (pseudomalignant) remodeling processes (thickening) of all vessel layers. Excessive proliferation of the vascular smooth muscle cells (SMC) is a prominent feature in virtually all forms of the disease. These remodeling processes lead to a severe loss of the cross-sectional area of the vessels, vascular pruning, and a concomitant increase in right ventricular afterload. Current PH therapy provides symptomatic relief and improves prognosis but falls short when it comes to recovering structural and functional lung vascular integrity, a prerequisite for symptom-free long-term survival. Restoration of the vascular structure and function (reverse remodeling) is the main goal of the research work carried out by the PH team.

Scientific Coordinators of the Disease Area

Prof. Dr. H. Ardeschir Ghofrani (UGMLC)
Prof. Dr. Ralph T. Schermuly (UGMLC)

Administrative Coordinator of the Disease Area

Dr. Sylvia Weißmann (UGMLC)

Participating DZL Partner Sites

all

News about Pulmonary Hypertension (PH)

8. January 2021

Study Examines Benefit of Pulmonary Hypertension Medication for Idiopathic Fibrosis

Patients with severe idiopathic pulmonary fibrosis (IPF) often develop additional pulmonary hypertension. A clinical trial investigated whether treatment with Sildenafil (approved for PH) when administered in addition to the pulmonary fibrosis medication pirfenidone is effective.
Read More
26. June 2020

Improved Diagnosis In Rare Form Of Pulmonary Hypertension

A research team from Hannover with participation of the DZL have published a study on molecular markers for various forms of pulmonary hypertension in the American Journal of Pathology.
Read More
18. June 2020

Over 13 Million Euros For New Therapies In Life-threatening Cardiopulmonary Diseases

The collaborative research center 1213 for cardiopulmonary research in Giessen, spear-headed by DZL scientist Prof. Dr. Norbert Weissmann, will be funded by the German Re-search Foundation (DFG) for another four years. The first funding period has already led to numerous successes.
Read More
All Pulmonary Hypertension (PH) news
chevron-down